NEOGEN CORP (NEOG) Stock Fundamental Analysis
NASDAQ:NEOG • US6404911066
10.94 USD
+0.16 (+1.48%)
At close: Feb 13, 2026
10.94 USD
0 (0%)
After Hours: 2/13/2026, 4:36:54 PM
Overall NEOG gets a fundamental rating of 3 out of 10. We evaluated NEOG against 186 industry peers in the Health Care Equipment & Supplies industry. While NEOG seems to be doing ok healthwise, there are quite some concerns on its profitability. NEOG is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year NEOG was profitable.
- NEOG had a positive operating cash flow in the past year.
- In multiple years NEOG reported negative net income over the last 5 years.
- In the past 5 years NEOG always reported a positive cash flow from operatings.
1.2 Ratios
- NEOG has a Return On Assets (-17.94%) which is comparable to the rest of the industry.
- Looking at the Return On Equity, with a value of -28.64%, NEOG is in line with its industry, outperforming 56.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.94% | ||
| ROE | -28.64% | ||
| ROIC | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 45.98%, NEOG is doing worse than 60.22% of the companies in the same industry.
- NEOG's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for NEOG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
- NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, NEOG has about the same amount of shares outstanding.
- The number of shares outstanding for NEOG has been increased compared to 5 years ago.
- NEOG has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.29, we must say that NEOG is in the distress zone and has some risk of bankruptcy.
- NEOG has a Altman-Z score (1.29) which is comparable to the rest of the industry.
- A Debt/Equity ratio of 0.38 indicates that NEOG is not too dependend on debt financing.
- The Debt to Equity ratio of NEOG (0.38) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.29 |
ROIC/WACCN/A
WACC9.96%
2.3 Liquidity
- NEOG has a Current Ratio of 3.91. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
- NEOG has a Current ratio of 3.91. This is in the better half of the industry: NEOG outperforms 66.67% of its industry peers.
- A Quick Ratio of 2.80 indicates that NEOG has no problem at all paying its short term obligations.
- NEOG's Quick ratio of 2.80 is fine compared to the rest of the industry. NEOG outperforms 63.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 2.8 |
3. Growth
3.1 Past
- NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.50%.
- Measured over the past years, NEOG shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.20% on average per year.
- The Revenue has decreased by -3.67% in the past year.
- NEOG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.43% yearly.
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%
3.2 Future
- The Earnings Per Share is expected to grow by 14.62% on average over the next years. This is quite good.
- Based on estimates for the next years, NEOG will show a small growth in Revenue. The Revenue will grow by 0.72% on average per year.
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y14.62%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y0.72%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- NEOG is valuated quite expensively with a Price/Earnings ratio of 37.72.
- Based on the Price/Earnings ratio, NEOG is valued a bit cheaper than 71.51% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.97. NEOG is valued slightly more expensive when compared to this.
- With a Price/Forward Earnings ratio of 32.26, NEOG can be considered very expensive at the moment.
- 71.51% of the companies in the same industry are more expensive than NEOG, based on the Price/Forward Earnings ratio.
- NEOG is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 27.96, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.72 | ||
| Fwd PE | 32.26 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 68.28% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 33.86 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.38%
EPS Next 3Y9.52%
5. Dividend
5.1 Amount
- NEOG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
10.94
+0.16 (+1.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-08 2026-01-08/bmo
Earnings (Next)04-07 2026-04-07
Inst Owners111.94%
Inst Owner Change-6.4%
Ins Owners0.61%
Ins Owner Change75.65%
Market Cap2.38B
Revenue(TTM)880.32M
Net Income(TTM)-602.74M
Analysts78.18
Price Target11.22 (2.56%)
Short Float %6.55%
Short Ratio3.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)87.17%
Min EPS beat(2)78.25%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)32.2%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)3
Avg EPS beat(8)11.3%
EPS beat(12)5
Avg EPS beat(12)119.18%
EPS beat(16)6
Avg EPS beat(16)37.27%
Revenue beat(2)2
Avg Revenue beat(2)3.22%
Min Revenue beat(2)0.46%
Max Revenue beat(2)5.99%
Revenue beat(4)2
Avg Revenue beat(4)0.6%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)5.99%
Revenue beat(8)3
Avg Revenue beat(8)0.18%
Revenue beat(12)4
Avg Revenue beat(12)-0.24%
Revenue beat(16)4
Avg Revenue beat(16)-0.78%
PT rev (1m)44.26%
PT rev (3m)44.26%
EPS NQ rev (1m)-20.69%
EPS NQ rev (3m)-20.69%
EPS NY rev (1m)22.22%
EPS NY rev (3m)22.22%
Revenue NQ rev (1m)2.17%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)3.31%
Revenue NY rev (3m)3.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.72 | ||
| Fwd PE | 32.26 | ||
| P/S | 2.7 | ||
| P/FCF | N/A | ||
| P/OCF | 35.91 | ||
| P/B | 1.13 | ||
| P/tB | N/A | ||
| EV/EBITDA | 33.86 |
EPS(TTM)0.29
EY2.65%
EPS(NY)0.34
Fwd EY3.1%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)0.3
OCFY2.78%
SpS4.05
BVpS9.68
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.94% | ||
| ROE | -28.64% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.98% | ||
| FCFM | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score4
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.38 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.98 | ||
| Cap/Depr | 71.99% | ||
| Cap/Sales | 9.62% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 74.97% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 2.8 | ||
| Altman-Z | 1.29 |
F-Score4
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y14.62%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y0.72%
EBIT growth 1Y-193.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year138.34%
EBIT Next 3Y34.61%
EBIT Next 5Y20.99%
FCF growth 1Y-209.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.22%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%
NEOGEN CORP / NEOG FAQ
What is the fundamental rating for NEOG stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEOG.
What is the valuation status of NEOGEN CORP (NEOG) stock?
ChartMill assigns a valuation rating of 2 / 10 to NEOGEN CORP (NEOG). This can be considered as Overvalued.
How profitable is NEOGEN CORP (NEOG) stock?
NEOGEN CORP (NEOG) has a profitability rating of 2 / 10.
What is the financial health of NEOGEN CORP (NEOG) stock?
The financial health rating of NEOGEN CORP (NEOG) is 4 / 10.
What is the expected EPS growth for NEOGEN CORP (NEOG) stock?
The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -9.33% in the next year.